JP2006512284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006512284A5 JP2006512284A5 JP2004508113A JP2004508113A JP2006512284A5 JP 2006512284 A5 JP2006512284 A5 JP 2006512284A5 JP 2004508113 A JP2004508113 A JP 2004508113A JP 2004508113 A JP2004508113 A JP 2004508113A JP 2006512284 A5 JP2006512284 A5 JP 2006512284A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- use according
- nucleus
- nucleic acid
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 claims 36
- 210000004027 cell Anatomy 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 18
- 108020004707 nucleic acids Proteins 0.000 claims 17
- 102000039446 nucleic acids Human genes 0.000 claims 17
- 230000010076 replication Effects 0.000 claims 13
- 108010049024 Viral Oncogene Proteins Proteins 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 108700020796 Oncogene Proteins 0.000 claims 9
- 108700019146 Transgenes Proteins 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 7
- 241000701161 unidentified adenovirus Species 0.000 claims 6
- 102000043276 Oncogene Human genes 0.000 claims 5
- 108700005077 Viral Genes Proteins 0.000 claims 5
- 230000004913 activation Effects 0.000 claims 5
- 238000012217 deletion Methods 0.000 claims 5
- 230000037430 deletion Effects 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 108091023037 Aptamer Proteins 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000000824 cytostatic agent Substances 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 230000029812 viral genome replication Effects 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 claims 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 claims 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 claims 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 claims 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 108010063312 Metalloproteins Proteins 0.000 claims 1
- 102000010750 Metalloproteins Human genes 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 1
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 1
- 230000002424 anti-apoptotic effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000030648 nucleus localization Effects 0.000 claims 1
- 108091008819 oncoproteins Proteins 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10223534.1 | 2002-05-27 | ||
| DE2002123534 DE10223534A1 (de) | 2002-05-27 | 2002-05-27 | Verwendung von Adenoviren und dafür codierenden Nukleinsäuren |
| DE10225400.1 | 2002-06-07 | ||
| DE10225400 | 2002-06-07 | ||
| DE10248039 | 2002-10-15 | ||
| DE10248039.7 | 2002-10-15 | ||
| DE10322530.7 | 2003-05-19 | ||
| DE10322530 | 2003-05-19 | ||
| PCT/EP2003/005583 WO2003099859A2 (de) | 2002-05-27 | 2003-05-27 | Neue verwendung von adenoviren und dafür codierenden nukleinsäuren |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116438A Division JP5719800B2 (ja) | 2002-05-27 | 2012-05-22 | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006512284A JP2006512284A (ja) | 2006-04-13 |
| JP2006512284A5 true JP2006512284A5 (enExample) | 2006-07-06 |
| JP5213298B2 JP5213298B2 (ja) | 2013-06-19 |
Family
ID=29587746
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004508113A Expired - Lifetime JP5213298B2 (ja) | 2002-05-27 | 2003-05-27 | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
| JP2012116438A Expired - Lifetime JP5719800B2 (ja) | 2002-05-27 | 2012-05-22 | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
| JP2014158673A Withdrawn JP2014224141A (ja) | 2002-05-27 | 2014-08-04 | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116438A Expired - Lifetime JP5719800B2 (ja) | 2002-05-27 | 2012-05-22 | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
| JP2014158673A Withdrawn JP2014224141A (ja) | 2002-05-27 | 2014-08-04 | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US20060099178A1 (enExample) |
| EP (1) | EP1506021B1 (enExample) |
| JP (3) | JP5213298B2 (enExample) |
| KR (1) | KR101083450B1 (enExample) |
| CN (2) | CN1655827B (enExample) |
| AU (2) | AU2003242585A1 (enExample) |
| CA (1) | CA2487811A1 (enExample) |
| WO (1) | WO2003099859A2 (enExample) |
| ZA (1) | ZA200409361B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003242585A1 (en) | 2002-05-27 | 2003-12-12 | Per Sonne Holm | Novel use of adenoviruses and nucleic acids coding therefor |
| EP1689445B1 (de) * | 2003-11-14 | 2015-02-25 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierende nukleinsäuren |
| WO2005052143A2 (de) * | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
| US8361976B2 (en) | 2004-07-09 | 2013-01-29 | University Of Massachusetts | Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules |
| EP1831382B1 (en) | 2004-12-31 | 2023-01-18 | Per Sonne Holm | Method for reversing multiple resistance in animal cells |
| US20090232800A1 (en) * | 2004-12-31 | 2009-09-17 | Per Sonne Holm | E1-minus adenoviruses and use thereof |
| WO2012022496A2 (en) | 2010-08-19 | 2012-02-23 | Per Sonne Holm | Method for killing tumor stem cells |
| SG11201507393TA (en) * | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| SG11202007873VA (en) * | 2018-03-05 | 2020-09-29 | Klinikum Rechts Der Isar Der Technischen Univ Muenchen | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| SG11202012978VA (en) | 2018-06-25 | 2021-01-28 | Ospedale San Raffaele Srl | Gene therapy |
| WO2021044061A1 (en) | 2019-09-05 | 2021-03-11 | Klinikum Rechts Der Isar Der Technischen Universität München | Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent |
| EP4123021A4 (en) * | 2020-03-23 | 2024-05-15 | Curigin Co.,Ltd. | STRUCTURE OF AN ONCOLYTIC VIRUS WITH BISPECIFIC NUCLEIC ACID MOLECULE |
| CN114540349B (zh) * | 2020-11-27 | 2024-11-22 | 中国科学院分子细胞科学卓越创新中心 | 结合yb-1蛋白的核酸分子 |
| CA3233100A1 (en) | 2021-09-23 | 2023-03-30 | Sagittarius Bio, Inc. | Adenoviruses and methods for using adenoviruses |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US931830A (en) * | 1907-09-17 | 1909-08-24 | Harry Zimmerman | Material-cutter. |
| US4947842A (en) | 1988-09-22 | 1990-08-14 | Medical Engineering And Development Institute, Inc. | Method and apparatus for treating tissue with first and second modalities |
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| DK0689447T3 (da) * | 1993-02-16 | 1999-10-18 | Onyx Pharma Inc | Cytopatiske vira til behandling af og profylakse for neoplasia |
| US5846945A (en) * | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
| EP0784690B1 (en) | 1994-06-10 | 2006-08-16 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US6326356B1 (en) * | 1996-10-18 | 2001-12-04 | Board Of Regents, The University Of Texas System | Suppression of neu overexpression using a mini-E1A gene |
| US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
| ATE386130T1 (de) | 1995-03-24 | 2008-03-15 | Genzyme Corp | Adenovirale vektoren für die gentherapie |
| US6676935B2 (en) | 1995-06-27 | 2004-01-13 | Cell Genesys, Inc. | Tissue specific adenoviral vectors |
| AU7674896A (en) | 1995-10-31 | 1997-05-22 | Board Of Regents, The University Of Texas System | Adenovirus-antisense k-ras expression vectors and their application in cancer therapy |
| US6022863A (en) | 1996-05-21 | 2000-02-08 | Yale University | Regulation of gene expression |
| US6730662B1 (en) * | 1996-07-05 | 2004-05-04 | Mcgill University | Adenovirus E4 proteins for inducing cell death |
| DE69725882T2 (de) | 1996-07-05 | 2004-07-29 | Branton, Philip E., St. Lambert | Adenovirus e4 proteine für induktion von zelltod |
| ES2188985T3 (es) | 1996-08-30 | 2003-07-01 | Jens Peter Furste | Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. |
| US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
| WO1998021350A1 (en) | 1996-11-13 | 1998-05-22 | Board Of Regents, The University Of Texas System | Diminishing viral gene expression by promoter replacement |
| US6080578A (en) | 1996-12-31 | 2000-06-27 | Onyx Pharmaceuticals, Inc. | Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia |
| US6100086A (en) | 1997-04-14 | 2000-08-08 | Genzyme Corporation | Transgene expression systems |
| DE69838584T2 (de) | 1997-08-04 | 2008-06-26 | Cell Genesys, Inc., Foster City | Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| EP1905304A3 (en) | 1997-10-09 | 2008-08-13 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
| CN1110553C (zh) * | 1998-07-15 | 2003-06-04 | 杭州赛狮生物技术开发有限公司 | 基因工程腺病毒及其用途 |
| EP1121442A2 (en) | 1998-10-15 | 2001-08-08 | CANJI, Inc. | Recombinant e1a deleted adenoviral vectors |
| US6649158B1 (en) | 1998-10-15 | 2003-11-18 | Canji, Inc. | Methods and compositions to induce antitumor response |
| DE19860602A1 (de) | 1998-12-29 | 2000-07-06 | Max Delbrueck Centrum | Gentransfervektor für die Diagnostik und die Therapie von malignen Tumoren |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| GB9906815D0 (en) | 1999-03-24 | 1999-05-19 | Isrec | Anti-neoplastic viral agents |
| DE19929569A1 (de) | 1999-06-21 | 2000-12-28 | Holm Per Sonne | Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1 |
| WO2001002556A2 (de) | 1999-06-30 | 2001-01-11 | Max-Delbrück-Centrum für Molekulare Medizin | Mittel zur diagnose, prognose und therapie maligner erkrankungen |
| US6955808B2 (en) | 1999-09-24 | 2005-10-18 | Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
| EP1223947A4 (en) * | 1999-10-15 | 2004-12-08 | Canji Inc | TARGETED VECTORS |
| US6140126A (en) | 1999-10-26 | 2000-10-31 | Isis Pharmaceuticals Inc. | Antisense modulation of Y-box binding protein 1 expression |
| WO2001036650A2 (en) * | 1999-11-15 | 2001-05-25 | Onyx Pharmaceuticals, Inc. | An oncolytic adenovirus |
| DE10015413A1 (de) | 2000-03-23 | 2001-09-27 | Max Delbrueck Centrum | Mittel zur Diagnose und Therapie viraler Erkrankungen |
| EP1301612A2 (en) | 2000-05-31 | 2003-04-16 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
| AU784975B2 (en) | 2000-10-11 | 2006-08-10 | Sumitomo Chemical Company, Limited | DNA-binding protein YB-1-containing collagen accumulation inhibitors |
| WO2002042468A2 (en) | 2000-11-27 | 2002-05-30 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
| US20030095989A1 (en) | 2000-12-18 | 2003-05-22 | Irving John M. | Chimeric cytolytic viruses for cancer treatment |
| DE50112463D1 (de) | 2000-12-28 | 2007-06-14 | Per Sonne Holm | Adenovirale systeme und deren anwendungen |
| DE10150945A1 (de) | 2001-10-16 | 2003-04-17 | Holm Per Sonne | Adenovirale Systeme und deren Anwendungen |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| JP3974894B2 (ja) | 2001-09-14 | 2007-09-12 | 財団法人新産業創造研究機構 | 腫瘍特異的プロモーターおよびその用途 |
| DE10150984A1 (de) | 2001-10-16 | 2003-04-17 | Holm Per Sonne | Verwendung des adenoviralen E2-late-Promotors |
| CA2478508C (en) | 2002-04-25 | 2013-07-02 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| AU2003242585A1 (en) | 2002-05-27 | 2003-12-12 | Per Sonne Holm | Novel use of adenoviruses and nucleic acids coding therefor |
| PL219321B1 (pl) | 2002-10-15 | 2015-04-30 | Per Sonne Holm | Adenowirus, kodujący go kwas nukleinowy, zawierający je układ replikacyjny, wektor, komórka i organizm, ich zastosowanie oraz środek farmaceutyczny |
| EP1616016B1 (en) | 2003-03-19 | 2012-11-14 | Isogenis, Inc. | Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain |
| EP1689445B1 (de) | 2003-11-14 | 2015-02-25 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierende nukleinsäuren |
| WO2005052143A2 (de) | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
| WO2006065827A2 (en) | 2004-12-13 | 2006-06-22 | Canji, Inc. | Cell lines for production of replication-defective adenovirus |
| EP1831382B1 (en) | 2004-12-31 | 2023-01-18 | Per Sonne Holm | Method for reversing multiple resistance in animal cells |
| US20090232800A1 (en) | 2004-12-31 | 2009-09-17 | Per Sonne Holm | E1-minus adenoviruses and use thereof |
| WO2007103825A2 (en) | 2006-03-02 | 2007-09-13 | The Board Of Regents Of The University Of Texas System | Combination therapy with oncolytic adenovirus |
-
2003
- 2003-05-27 AU AU2003242585A patent/AU2003242585A1/en not_active Abandoned
- 2003-05-27 WO PCT/EP2003/005583 patent/WO2003099859A2/de not_active Ceased
- 2003-05-27 CN CN03812310XA patent/CN1655827B/zh not_active Expired - Fee Related
- 2003-05-27 JP JP2004508113A patent/JP5213298B2/ja not_active Expired - Lifetime
- 2003-05-27 EP EP03755145.4A patent/EP1506021B1/de not_active Expired - Lifetime
- 2003-05-27 KR KR1020047019231A patent/KR101083450B1/ko not_active Expired - Fee Related
- 2003-05-27 CN CN201010161559.4A patent/CN101843641B/zh not_active Expired - Fee Related
- 2003-05-27 CA CA002487811A patent/CA2487811A1/en not_active Abandoned
- 2003-05-27 US US10/515,238 patent/US20060099178A1/en not_active Abandoned
-
2004
- 2004-11-22 ZA ZA2004/09361A patent/ZA200409361B/en unknown
-
2010
- 2010-04-28 US US12/769,435 patent/US10155930B2/en not_active Expired - Lifetime
- 2010-09-09 AU AU2010219364A patent/AU2010219364B2/en not_active Ceased
-
2012
- 2012-05-22 JP JP2012116438A patent/JP5719800B2/ja not_active Expired - Lifetime
-
2014
- 2014-08-04 JP JP2014158673A patent/JP2014224141A/ja not_active Withdrawn
-
2017
- 2017-03-07 US US15/452,470 patent/US10538744B2/en not_active Expired - Fee Related
-
2018
- 2018-10-31 US US16/176,461 patent/US10731136B2/en not_active Expired - Fee Related
-
2019
- 2019-12-05 US US16/704,669 patent/US11268073B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11268073B2 (en) | Use of adenovirus and nucleic acids coding therefor | |
| JP5618896B2 (ja) | 新規アデノウイルス、それをコードする核酸及びその使用 | |
| Zhu et al. | Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo | |
| JP2021097701A (ja) | 内皮特異的核酸調節エレメントならびにその方法および使用 | |
| JP2008526188A5 (enExample) | ||
| JP2019520814A5 (enExample) | ||
| JP5435871B2 (ja) | Ｅ１−マイナスアデノウイルス及びその使用 | |
| JP2008526189A5 (enExample) | ||
| JP2008526188A (ja) | 動物細胞における多剤耐性を逆転させる方法 | |
| US12371670B2 (en) | Fast and accurate three-plasmid oncolytic adenovirus recombinant packaging system Ad5MixPlus and application thereof | |
| JP2006518589A5 (enExample) | ||
| Li et al. | Recombinant adenovirus encoding vasohibin prevents tumor angiogenesis and inhibits tumor growth | |
| CN1984996B (zh) | 能够沉默病毒抑制因子表达的可复制病毒 | |
| Chang et al. | Durable expression of minicircle DNA‐liposome‐delivered androgen receptor cDNA in mice with hepatocellular carcinoma | |
| Sonabend et al. | Oncolytic adenoviral therapy for glioblastoma multiforme | |
| Iizuka et al. | Evaluation of transduction properties of an adenovirus vector in neonatal mice | |
| JP2005505299A (ja) | アデノウイルスｅ２後期プロモーターの使用 | |
| RU2522810C1 (ru) | Носитель для направленной доставки нуклеиновых кислот в клетки, экспрессирующие рецептор cxcr4 | |
| RU2004138095A (ru) | Новое применение аденовируса и кодирующих его нуклеиновых кислот | |
| JP2005530495A (ja) | オールターナティブスプライシングされる核酸分子 | |
| AU2015201828B2 (en) | Novel use of adenoviruses and nucleic acids coding therefor | |
| RU2005114516A (ru) | Аденовирус с обращенной генной экспрессией и его применение | |
| CN1705740B (zh) | 具有反向基因表达的腺病毒及其应用 | |
| Vonka | Gene Therapy: Hopes and Problems | |
| Shimizu et al. | 382 Identification of peptides binding to hepatocellular carcinoma |